Incyte | INCY - Cash And Equivalent

Stock Price
94.44
Daily Change
-0.75 -0.79%
Monthly
-2.56%
Yearly
44.62%
Q2 Forecast
93.39

Incyte reported $4.02B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Agenus USD 35M 32M Mar/2026
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Eli Lilly USD 5.28B 1.99B Mar/2026
Exelixis USD 226.15M 256.34M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
Incyte USD 4.02B 435.22M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
MacroGenics USD 66.52M 9.3M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Moderna USD 1.91B 687M Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.7B 561M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026